Swiss National Bank’s CytomX Therapeutics CTMX Stock Holding History

Swiss National Bank’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.22M	Buy	325,400 +5,800	+2%	+$22.1K	﹤0.01%	2154
2026 Q1	$1.5M	Buy	+319,600	New	+$1.62M	﹤0.01%	1987
2021 Q4	–	Sell	-116,200	Closed	-$591K	–	2729
2021 Q3	$591K	Hold	116,200	–	–	﹤0.01%	2563
2021 Q2	$736K	Hold	116,200	–	–	﹤0.01%	2566
2021 Q1	$898K	Buy	116,200 +22,200	+24%	+$176K	﹤0.01%	2373
2020 Q4	$616K	Buy	94,000 +2,700	+3%	+$19.3K	﹤0.01%	2432
2020 Q3	$607K	Hold	91,300	–	–	﹤0.01%	2317
2020 Q2	$761K	Buy	91,300 +4,400	+5%	+$40.9K	﹤0.01%	2251
2020 Q1	$667K	Hold	86,900	–	–	﹤0.01%	2041
2019 Q4	$722K	Buy	86,900 +3,000	+4%	+$20.2K	﹤0.01%	2292
2019 Q3	$619K	Hold	83,900	–	–	﹤0.01%	2282
2019 Q2	$941K	Buy	83,900 +6,000	+8%	+$62.9K	﹤0.01%	2148
2019 Q1	$837K	Buy	77,900 +2,400	+3%	+$35.5K	﹤0.01%	2166
2018 Q4	$1.14M	Buy	75,500 +2,700	+4%	+$40.1K	﹤0.01%	1926
2018 Q3	$1.35M	Buy	72,800 +12,600	+21%	+$287K	﹤0.01%	1973
2018 Q2	$1.38M	Buy	60,200 +24,600	+69%	+$628K	﹤0.01%	1965
2018 Q1	$1.01M	Buy	35,600 +2,200	+7%	+$62.8K	﹤0.01%	2071
2017 Q4	$705K	Hold	33,400	–	–	﹤0.01%	2287
2017 Q3	$607K	Hold	33,400	–	–	﹤0.01%	2312
2017 Q2	$518K	Buy	33,400 +6,600	+25%	+$99.5K	﹤0.01%	2392
2017 Q1	$463K	Buy	26,800 +4,300	+19%	+$56.6K	﹤0.01%	2402
2016 Q4	$247K	Hold	22,500	–	–	﹤0.01%	2533
2016 Q3	$353K	Hold	22,500	–	–	﹤0.01%	2445
2016 Q2	$230K	Buy	+22,500	New	+$257K	﹤0.01%	2550

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Swiss National Bank's CTMX Position: Q2 2026 in Review

Swiss National Bank increased its CytomX Therapeutics (CTMX) stake by 1.8% in Q2 2026, buying an estimated $22.1K and bringing the position to 325,400 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.

Swiss National Bank first reported a position in CTMX in Q2 2016 and has held it in 24 quarters since. The position peaked at $1.5M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Swiss National Bank held 325,400 shares of CytomX Therapeutics worth $1.22M as of Q2 2026.
Swiss National Bank bought 5,800 CytomX Therapeutics shares in Q2 2026, an estimated $22.1K.
CytomX Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2154 holding.
Swiss National Bank first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 24 quarters since.
Swiss National Bank's CytomX Therapeutics position peaked at $1.5M in Q1 2026.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.